Article

A simple and robust clinical manufacturing process for the ex-vivo expansion of autologous T cells genetically engineered to express an anti-BCMA chimeric antigen receptor (CAR) for the treatment of multiple myeloma

2015-01-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1c1f2877-a9d9-5c49-bc0c-280c2bdc05e3
DOI: 10.1186/2051-1426-3-s2-p117
PMCID: PMC4646118

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A simple and robust clinical manufacturing process for the ex-vivo expansion of autologous T cells genetically engineered to express an anti-BCMA chimeric antigen receptor (CAR) for the treatment of multiple myelomaDOI 10.1186/2051-1426-3-s2-p117Read

Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trialSemantic proximity Read

Global Manufacturing of CAR T Cell TherapySemantic proximity Read

Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use.Semantic proximity Read

CAR T Cell Therapy: A Versatile Living DrugSemantic proximity Read

Revolutionizing CAR T Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and AccessibilitySemantic proximity Read

Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic functionSemantic proximity Read

Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapiesSemantic proximity Read

A closed, autologous bioprocess optimized for TCR-T cell therapiesSemantic proximity Read

Chimeric Antigen Receptor T-Cell Therapy: What We Expect SoonSemantic proximity Read

Optimizing the manufacturing and antitumour response of CAR T therapySemantic proximity Read

A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptorSemantic proximity Read

CAR T-cell therapy in multiple myeloma: mission accomplished?Semantic proximity Read